Epigenetics Reveals Hidden Heart Disease Risks

When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself. Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform.

Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution. Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls that reading process, influenced by factors like diet, exercise, stress, and environmental exposures. By analyzing epigenetic markers, Cardio Diagnostics can provide invaluable insight into the impact of lifestyle, behavior, and environment on an individual’s heart health, offering a more dynamic and personalized risk assessment than traditional genetic testing.

This approach represents a paradigm shift in cardiovascular care, moving beyond static genetic predispositions to a real-time view of current risk. For patients, this means potentially earlier detection and more actionable guidance for prevention. For the medical community, it offers a tool to tailor interventions based on an individual's unique epigenetic profile. Cardio Diagnostics is leveraging this science to uncover hidden heart disease risks that might otherwise go unnoticed until a clinical event occurs. As the company continues to develop its platform, the potential to reduce the burden of heart disease through personalized, epigenetics-driven diagnostics is becoming increasingly tangible. For more information, visit the company’s newsroom at https://ibn.fm/CDIO.